Targeting key vulnerabilities in these models, including SERPINE1 inhibitors and cholesterol metabolism with statins, may provide an effective strategy for overcoming oxaliplatin resistance in the clinic, ultimately improving outcomes for patients with metastatic CRC. This evidence concerns the gene SERPINE1 and colorectal carcinoma.